These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 30522786)
1. PCSK9: from biology to clinical applications. Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G Pathology; 2019 Feb; 51(2):177-183. PubMed ID: 30522786 [TBL] [Abstract][Full Text] [Related]
2. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. Bittner VA; Giugliano RP; Brinton EA; Guyton JR J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750 [TBL] [Abstract][Full Text] [Related]
3. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation. Weider E; Susan-Resiga D; Essalmani R; Hamelin J; Asselin MC; Nimesh S; Ashraf Y; Wycoff KL; Zhang J; Prat A; Seidah NG J Biol Chem; 2016 Aug; 291(32):16659-71. PubMed ID: 27284008 [TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol. Wang Y; Liu ZP Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249 [TBL] [Abstract][Full Text] [Related]
6. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Della Badia LA; Elshourbagy NA; Mousa SA Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571 [TBL] [Abstract][Full Text] [Related]
7. A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases. Chen B; Shi X; Cui Y; Hou A; Zhao P Curr Top Med Chem; 2019; 19(20):1790-1817. PubMed ID: 31400268 [TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events. Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008 [TBL] [Abstract][Full Text] [Related]
9. The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. Seidah NG; Abifadel M; Prost S; Boileau C; Prat A Pharmacol Rev; 2017 Jan; 69(1):33-52. PubMed ID: 27920219 [TBL] [Abstract][Full Text] [Related]
11. New developments in proprotein convertase subtilisin-kexin 9's biology and clinical implications. Seidah NG Curr Opin Lipidol; 2016 Jun; 27(3):274-81. PubMed ID: 27031271 [TBL] [Abstract][Full Text] [Related]
12. PCSK9 Biology and Its Role in Atherothrombosis. Barale C; Melchionda E; Morotti A; Russo I Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931 [TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748 [TBL] [Abstract][Full Text] [Related]
18. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects]. Pedro-Botet J; Badimón L Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Athyros VG; Tziomalos K; Doumas M; Sfikas G; Karagiannis A Curr Pharm Des; 2017; 23(10):1477-1483. PubMed ID: 28128061 [TBL] [Abstract][Full Text] [Related]
20. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]